management tweak guidanc back
penalti box
isnt one thing seem anoth come
somewhat spotti record come provid guidanc
affect seri one-off event past year half seem
bit two step forward one step back investor present
morn manag made cautiou commentari near-term sale
outlook recent tax regul propos surpris reaction
stock close vs market take consider
manag comment lower ep estim reduc price
target reflect lower earn outlook well lower target price-to-earnings given lack
consist /predict maintain overweight rate time given
valuat longer term growth prospect pipelin
softer cvg sale expect expect sale mid-point
full year rang versu high end due modest growth
cardiac vascular group cvg specif experienc soft
left ventricular assist devic lvad busi well cautious around drug-
coat balloon dcb follow journal articl rais question safeti
dcb gener latter could also affect bdx-equal weight
recent tax propos creat headwind manag comment tax rate
could see increas due recent tax regul propos
result ep growth like fall target long-term growth rate
valuat risk weve trim ep reduc ep
revis pt prior appli vs price-to-earnings calendar
ep vs risk includ new product approv advers fx
rate stronger us dollar competit product launch regulatori action chang
reimburs success integr dilut
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
today investor present manag said continu believ
robust pipelin compani histori manag highlight number
new product across four busi unit howev manag offer
manag revis guidanc cvg expect
grow /-
revis guidanc due follow issu
lvad soft expect slower growth left ventricular assist devic
lvad busi due two factor first earlier expect receipt
abbott heartmat brought addit competit
headwind second chang unit network organ share uno
guidelin juli creat greater avail heart transplant
sever journal articl call question safeti paclitaxel drug use
commerci avail drug-coat balloon dcb compani note work
fda plan present patient level analysi upcom leipzig
intervent cours linc confer late januari well upcom viva
summit may note could also neg implic becton
dickinson dcb busi well
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
co usd equal weight/posit a/cd/ce/d/j/k/l/m/n
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
gd one analyst fundament credit coverag team member household financi interest debt
equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest debt
equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or relat
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens brokerag
